M2M News


Recent Center News

Innovative interdisciplinary research, training, and technology development from the M2M at the University of Massachusetts Amherst.
Jeanne Hardy and Jasna Fejzo
  • IALS | M2M | Core Facilities 

NMR Core Facility Receives $4.4 Million from MLSC for Advanced Atomic Resolution Instrument

IALS has received more than $4.4 million from the Massachusetts Life Sciences Center (MLSC) to acquire an 800 MHz Nuclear Magnetic Resonance (NMR) spectrometer. This high-field atomic resolution instrument will aid researchers working to develop the next generation of drugs to treat high unmet-need diseases, including various types of cancer and Alzheimer’s disease.

Learn More
Sarah Perry, PhD
  • CBD | M2M 

Sarah Perry to Receive American Chemical Society Young Investigator Award

Sarah Perry, associate professor in the Department of Chemical Engineering, Center for Bioactive Delivery, Models to Medicine Center, has been chosen as one of two national recipients of the 2024 American Chemical Society (ACS) Macro Letters/Biomacromolecules/Macromolecules Young Investigator Award for her contributions to the field of polyelectrolyte self-assembly and the incorporation of proteins into these assemblies.

Learn More
Alicia Timme-Laragy, PhD
  • IALS | M2M 

Alicia Timme-Laragy Offers Expertise to National Academies Committee on Role of Seafood in Child Development

Alicia Timme-Laragy, professor of environmental health sciences, Models to Medicine Center, whose research focuses on developmental toxicology and environmental pollutants, recently served as an expert consultant for the National Academies Committee for their study, “The Role of Seafood in Child Growth and Development,” for the U.S. Food and Drug Administration (FDA).

Learn More
Craig Martin and Sarah Perry
  • CBD | M2M 

Martin and Perry to Help Launch the Future of RNA Research and Biomedicine

Craig Martin, professor of chemistry, Models to Medicine Center, and Sarah Perry, associate professor of chemical engineering, Center for Bioactive Delivery, recently received support from the National Institutes of Health (NIH) to develop an innovative approach toward efficiently, reliably and cost effectively synthesizing novel strands of specialty “long RNA.” Future genetic research into everything from basic cell biology to advanced therapeutics depends in part on having just the sort of complex, modified RNA that Martin and Perry will be working to make widely available.

Learn More